Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Feature|Articles|May 26, 2026
- Vol.27/No.7
Novel Proton Therapy Techniques and EGFR-Directed Agents Drive the Future of Head and Neck Cancer Care
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Afton Woodward
Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.
Advertisement
Advertisement
Innovative targeted agents and specified proton therapy applications are among the most promising evolving strategies for head and neck cancer management, providing a foundation for future patient care that is highly individualized and provides enduring treatment options for patients who have received prior lines of therapy.
Related to this article
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
Advertisement
Advertisement